单词 | ganciclovir |
释义 | ganciclovirgan·ci·clo·virG5033600 (găn-sī′klō-vîr′, -klə-)ganciclovirganciclovir[gan-si´klo-vir]ganciclovir (DHPG)Pharmacologic class: Acyclic purine nucleoside analog of 2′-deoxyguanosine Therapeutic class: Antiviral Pregnancy risk category C ActionInhibits binding of deoxyguanosine triphosphate to DNA polymerase by terminating DNA synthesis, thereby inhibiting viral replication AvailabilityCapsules: 250 mg, 500 mg Injection: 500 mg/vial Intravitreal implant: 4.5 mg Indications and dosages➣ Prevention of CMV in advanced human immunodeficiency virus (HIV) infection Adults: 1,000 mg P.O. t.i.d. ➣ Prevention of CMV in transplant recipients Adults: 5 mg/kg I.V. q 12 hours for 7 to 14 days; then 5 mg/kg/day 7 days per week or 6 mg/kg/day 5 days per week ➣ CMV retinitis in immunocompromised patients Adults and children ages 9 and older: Intravitreal implant (4.5 mg) placed during intraocular surgery Adults and children older than 3 months: Initially, 5 mg/kg I.V. q 12 hours for 14 to 21 days, followed by a maintenance dosage of 5 mg/kg/day 7 days per week or 6 mg/kg 5 days per week. For P.O. maintenance, 1,000 mg P.O. t.i.d. or 500 mg P.O. q 3 hours while patient is awake. Dosage adjustment• Renal impairment • Elderly patients Off-label uses• CMV gastroenteritis, CMV pneumonia Contraindications• Hypersensitivity to drug or acyclovir • Neutropenia or thrombocytopenia • Contraindications for intraocular surgery, such as external infections or thrombocytopenia (with intravitreal implant) • Breastfeeding PrecautionsUse cautiously in: • renal impairment • history of cytopenic reactions • pregnant patients • children younger than age 9 (with intravitreal implant). AdministrationSee Follow facility policy for handling and disposing of antineoplastic drugs. (Drug shares some properties with antitumor agents.) • Be aware that safety and efficacy of I.V. use haven't been established for congenital or neonatal CMV disease, treatment of established CMV disease other than retinitis, or use in nonimmunocompromised individuals. See Don't let powder in capsules or I.V. solution contact skin, eyes, or mucous membranes. If contact occurs, wash skin thoroughly with soap and water, or flush eyes with water. • Reconstitute 500-mg vial with 10 ml of sterile water; shake vial to dissolve drug. Then dilute drug again in 50 to 250 ml of compatible I.V. solution. • If patient is on fluid restriction, dilute to a concentration of 10 mg/ml or less. See Administer a single dose by I.V. infusion slowly (over at least 1 hour), using infusion pump or microdrip (60 gtt/ml). • Give I.V. solution within 24 hours of dilution to reduce risk of bacterial contamination. See Don't give by I.V. bolus or by I.M. or subcutaneous route. • Administer oral doses with food. • Be aware that intravitreal implant is designed to release drug over 5 to 8 months. Once drug is depleted (as shown by retinitis progression), implant may be removed and replaced. See Handle intravitreal implant carefully by suture tab only, to avoid damage to polymer coating. (Damage could increase rate of drug release.) Adverse reactionsCNS: ataxia, confusion, dizziness, headache, drowsiness, tremor, abnormal thinking, agitation, amnesia, neuropathy, paresthesia, seizures, coma CV: hypertension, hypotension, phlebitis, arrhythmias EENT: vision loss for 2 to 4 weeks, vitreous loss, vitreous hemorrhage, cataract, retinal detachment, uveitis, endophthalmitis (all with intravitreal implant) GI: nausea, vomiting, diarrhea, abdominal pain, dyspepsia, flatulence, anorexia, dry mouth Hematologic: anemia, agranulocytosis, thrombocytopenia, leukopenia Respiratory: pneumonia Skin: rash, diaphoresis, pruritus Other: fever; infection; chills; inflammation, pain, and phlebitis at injection site; sepsis InteractionsDrug-drug. Amphotericin B, cyclosporine, other nephrotoxic drugs: increased risk of renal impairment and ganciclovir toxicity Cilastatin, imipenem: increased seizure activity Cytotoxic drugs: increased toxic effects Immunosuppressants: increased immunologic and bone marrow depression Probenecid: increased ganciclovir blood level Zidovudine: increased risk of agranulocytosis Drug-diagnostic tests. Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, creatinine, gamma-glutamyltransferase: increased values Granulocytes, hemoglobin, neutrophils, platelets, white blood cells: decreased values Liver function tests: abnormal results Patient monitoring• Monitor liver function test results. • Monitor neutrophil and platelet counts. • Assess fluid intake and output to ensure adequate hydration. • Make sure patient has regular ophthalmic examinations during both induction and maintenance therapy. See Monitor neurologic status closely; watch for seizures and coma. See Check for signs and symptoms of infection, particularly sepsis. Patient teachingSee Advise patient to immediately report signs and symptoms of infection, including those at infusion site. See Instruct patient to immediately report easy bruising or bleeding. • Instruct patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness. • Caution female patient not to breastfeed. • Inform patient that drug may cause birth defects. Tell females to use effective birth control during therapy; advise males to use barrier contraception during and for 90 days after therapy. See Caution patient not to open or crush capsule. If powder from capsule contacts skin or eyes, tell him to wash skin thoroughly with soap and water or flush eyes with water. • Instruct patient to minimize GI upset by eating frequent, small servings of healthy food. • Tell patient he'll undergo regular blood testing during therapy. • Explain that drug doesn't cure CMV retinitis and that patient should have eye exams every 4 to 6 weeks during therapy. • As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above. ganciclovir(găn-sī′klō-vîr′, -klə-)ganciclovirCytovene, DHPG Virology An IV protease inhibiting antiviral used for CMV-induced retinitis, gastroenteritis, and hepatitis and other infections, eliminating CMV from blood, urine and respiratory secretions Indications Immunosuppression 2º to AIDS, BMT, chemotherapy Adverse events Severe neutropenia/sepsis, changed mental status, thrombocytopenia. See Cytomegalovirus. Cf Acyclovir.ganciclovirA DNA POLYMERASE INHIBITOR drug used to treat CYTOMEGALOVIRUS infections in people with AIDS. Brand names are Cymevene and Virgan.antiviral agents |
随便看 |
|
英语词典包含2567994条英英释义在线翻译词条,基本涵盖了全部常用单词的英英翻译及用法,是英语学习的有利工具。